Analyst firms · Morgan Stanley · SGHT
Morgan Stanley SGHT price target and rating history
Sight Sciences Inc. (SGHT) · Health Care
Morgan Stanley rates Sight Sciences Inc. (SGHT) Equal-Weight with a $8.40 price target, as of its latest action on Aug 24, 2023. It has published 3 rating actions on SGHT since August 2021, including 1 upgrade and 1 downgrade. Across 3 firms with a SGHT price target in the last 12 months, the median target is $9.
- Current rating
- Equal-Weight
- Price target
- $8.40
- Median target, all firms
- $9
- Actions on SGHT
- 3
Morgan Stanley price target on SGHT
Every Morgan Stanley rating on SGHT
- Aug 24, 2023
- Jan 7, 2022
- Aug 9, 2021
How other firms rate SGHT
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| H.C. Wainwright | Buy | $14 | Oct 15, 2026 |
| UBS | Buy | $7 | Jul 28, 2026 |
| Piper Sandler | Overweight | $9 | Jan 5, 2026 |
Questions about Morgan Stanley and SGHT
- What is Morgan Stanley's price target for SGHT?
- Morgan Stanley's latest stated price target for Sight Sciences Inc. (SGHT) is $8.40, from its action on Aug 24, 2023.
- What is Morgan Stanley's rating on SGHT?
- Morgan Stanley rates SGHT Equal-Weight, a neutral rating, as of Aug 24, 2023.
- When did Morgan Stanley last change its view on SGHT?
- On Aug 24, 2023, Morgan Stanley downgrades to Equal-Weight from Overweight, price target $12 to $8.40.
- How does Morgan Stanley's SGHT target compare with other analysts?
- Across 3 firms with a SGHT price target in the last 12 months, the median target is $9.
More SGHT rating histories
All Morgan Stanley ratingsSGHT news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.